Cell and gene therapies
-
TGA approves second siRNA
- 28 Nov 2022
As the first siRNA cardio therapy returns to PBAC, the TGA has approved a sister therapy treating a very different condition.
Read more -
MSAC CAR-T decision stuns clinicians
- 11 Nov 2022
Australia’s vision to be a manufacturing hub for CAR-T is at risk with MSAC putting out signals that the country is not ready.
Read more -
MSAC roadblock a CAR-T setback
- 09 Nov 2022
Clinicians say call it ‘transformative’, patients are dying without it, but it seems large-scale access to CAR-T won’t happen in Australia anytime soon.
Read more -
BioNTech in Aussie CAR-T deal
- 23 Sep 2022
The German mRNA is working with an Aussie company on cell therapies as it looks to the next big thing.
Read more -
Where is Gilead’s second CAR-T?
- 19 Sep 2022
More than a year after it was recommended by MSAC, Gilead’s second CAR-T is still not available. Health and Gilead have different views as to why.
Read more -
Clinicians ready for myeloma ‘cure’
- 14 Sep 2022
CAR-T is coming in multiple myeloma, says a leading haematologist, while flagging another new class of therapies is ‘hot on its heels’.
Read more -
CRISPR, vaccines, nanobots Aust-critical
- 24 Aug 2022
A new industry consultation paper opens discussion on cutting-edge medical processes, and how they fit into Australia’s future.
Read more -
Bluebird bio secures gene approval
- 19 Aug 2022
FDA approval of Zynteglo ‘monumental’ for patients as the company reveals it has a price tag of $4 million.
Read more